Clinical trial · Observational
Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enzyme-linked immunosorbent assay | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- the newly diagnosed group
- interventionNames
- Diagnostic Test: Enzyme-linked immunosorbent assay
- label
- the relapsed group
- interventionNames
- Diagnostic Test: Enzyme-linked immunosorbent assay
- label
- the complete remission group
- interventionNames
- Diagnostic Test: Enzyme-linked immunosorbent assay
- label
- the control group
- interventionNames
- Diagnostic Test: Enzyme-linked immunosorbent assay
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:
* In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ②Leukocyte count ≤ 25×109/L;
* No treatment has been received in the past 6 months.
* None of the candidates are related and known this study, and sign the informed consent.
Exclusion Criteria:
* Patients who are allergic to the drugs used in this study;
* People with mental illness or cognitive impairment;
* Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.References
Publications (0)
Data not yet available